How the Narrative Surrounding Kura Oncology Is Changing After Komzifti Approval [Yahoo! Finance]
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: Yahoo! Finance
slightly stronger long term growth and a touch more perceived risk. Fair value remains anchored at an implied $33 per share. A small uptick in the discount rate and a marginal increase in expected revenue growth indicate that Komzifti is now modeled as a near certain commercial contributor rather than a probability weighted option. Stay tuned to see how you can track these evolving assumptions and the shifting story behind Kura Oncology's valuation over time. Stay updated as the Fair Value for Kura Oncology shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Kura Oncology. ?? Bullish Takeaways BofA analyst Jason Zemansky characterizes the FDA approval of ziftomenib, now branded as Komzifti, as a "watershed moment for the company," reinforcing a Buy rating on Kura Oncology. BofA raised its price target to $30 from $29 as it now assigns a 100% probability of commercial success to Komzifti, a shift from earlier
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- Jim Cramer Discusses Kura Oncology as a Speculative Bet [Yahoo! Finance]Yahoo! Finance
- Is it time to get into biopharma player Kura Oncology? Jim Cramer digs in [CNBC]CNBC
- Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AMLGlobeNewswire
- Why The Narrative Around Kura Oncology Is Shifting After Komzifti's FDA Breakthrough [Yahoo! Finance]Yahoo! Finance
- Kura Oncology (NASDAQ:KURA) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
KURA
Earnings
- 11/4/25 - Miss
KURA
Sec Filings
- 12/19/25 - Form 4
- 12/18/25 - Form 144
- 12/10/25 - Form 4
- KURA's page on the SEC website